Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?

Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?

Aim:This study aims to identify suitable candidates for axillary sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) among clinical N2 (cN2) triple-negative (TN) or HER2 positive (HER2+）breast cancer patients following neoadjuvant therapy（NAT）.Background: Despite the substantial...

Full description

Bibliographic Details
Main Authors: Xuhui Guo, Jiao Zhang, Xilong Gong, Jia Wang, Hao Dai, Dechuang Jiao, Rui Ling, Yi Zhao, Hongjian Yang, Yunjiang Liu, Ke Liu, Jianguo Zhang, Dahua Mao, Jianjun He, Zhigang Yu, Yinhua Liu, Peifen Fu, Jiandong Wang, Hongchuan Jiang, Zuowei Zhao, Xingsong Tian, Zhongwei Cao, Kejin Wu, Ailin Song, Feng Jin, Zhimin Fan, Zhenzhen Liu
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Breast
Online Access:http://www.sciencedirect.com/science/article/pii/S096097762400002X

Internet

http://www.sciencedirect.com/science/article/pii/S096097762400002X

Similar Items